News & analysis, rated.
Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.
Biogen's SMA Drug Wins FDA Breakthrough for Once-Yearly Dosing
Salanersen (BIIB115) earned FDA breakthrough designation based on Phase Ib data showing motor function gains in children who failed gene therapy. Three Phase III trials now underway.
Pfizer Licenses Chai-3 AI Model for Drug Discovery
Pfizer gains early access to Chai Discovery's Chai-3 model, which doubled antibody design success rates. The deal signals pharma's shift toward generative AI for accelerating biologics discovery.
ASCO 2026: Oncology analysts name the readouts that moved the market
GlobalData oncology analysts Jack Cuthbertson and Selena Yu walk through their top clinical readouts from ASCO 2026, including standouts in ADCs, cancer vaccines, and bispecific antibodies.
Parabilis raises $475M to take zolucatetide to Phase III trials
Regeneron-backed biotech Parabilis plans to spend $150M of IPO proceeds on a registrational trial for its β-catenin inhibitor in desmoid tumours, competing directly with SpringWorks' approved Ogsiveo.
Joachim Eeckhout built Labiotech from a bike tour. Now he's plotting what comes next
Episode 200 marks Labiotech's milestone: a founder reflects on building Europe's largest biotech media platform, the acquisition by IN-PART in 2021, and where science communication heads next.
Stipple Bio and Lonza Partner on Tumor-Specific Antibody Cancer Drugs
Stipple Bio licensed Lonza's antibody conjugation and linker technology to develop ADC cancer therapies that target tumor cells while sparing healthy tissue. The deal includes milestone payments and royalties.
MIT Lab Adds Mucosal Immunity to Injectable Polio Vaccine
Researchers paired an experimental adjuvant with the injectable polio vaccine to trigger gut-level immunity in rats, potentially closing a transmission gap that oral vaccines fill but carry safety risks.
Lab Leaders and AI Experts Back Mandatory DNA Synthesis Screening
A coalition of biotech CEOs, AI researchers, and national security officials signed an open letter June 3 calling on Congress to mandate screening of synthetic DNA orders. Here's what the guardrail covers and why the timing matters.
Cells use antibody-tagged viruses to trigger self-defense autophagy
Researchers mapped a previously unknown intracellular pathway where TRIM21 protein flags antibody-coated bacteria and viruses for digestion, blocking Salmonella and adenovirus infection inside cells.
D&D-seq Maps Weak Protein-DNA Contacts in Single Cells
A new method using base editing and nanobodies captures fleeting transcription factor binding that traditional ChIP-seq misses. Researchers can now profile regulatory proteins in individual cells alongside gene expression and chromatin data.
Pharma's PD-1/VEGF bet may target wrong cancer. Liver shows more promise than lung.
Drug makers are chasing PD-1/VEGF bispecifics in lung cancer, but clinical evidence suggests the liver is a stronger indication. Here's what that shift means for your pipeline.
House moves to block China biotech deals after Pfizer, Bristol Myers moves
A bipartisan bill would add biotechnology to the COINS Act, restricting Chinese investment in U.S. drug development. The push follows major pharma acquisitions and U.S. concerns about China's drugmaking progress.